New drug cocktail targets tough lung cancer mutations
NCT ID NCT05491811
First seen May 07, 2026 · Last updated May 07, 2026
Summary
This study tests a combination of two drugs, ensartinib and bevacizumab, in people with advanced lung cancer that has specific genetic changes (ALK rearrangement and TP53 mutation). The goal is to see if the combo can keep the cancer from growing for at least 12 months. About 47 participants will receive the treatment, and researchers will monitor how well it works and any side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Sun Yat-Sen University Cancer Center
Guangzhou, Guangdong, China
Conditions
Explore the condition pages connected to this study.